MyTomorrows and Emmaus Life Sciences Inc. to Collaborate on Early Access Program for Sickle Cell Disease Treatment in the EU, Turkey, Middle-East and South America
January 08, 2018 at 05:00 am
Share
myTomorrows and Emmaus Life Sciences, Inc. announced the availability of an Early Access Program for pharmaceutical grade L-Glutamine (oral powder) for the treatment of Sickle Cell Disease patients that have exhausted other remaining treatment options. This Early Access Program, currently run on a named patient basis, provides physicians in the EU, Turkey, Middle-east and South America with the possibility to prescribe L-Glutamine to eligible patients prior to authorization. L-Glutamine was approved in the US on 7 July 2017 under the trade name Endari™ for the treatment of Sickle Cell Disease in adult and paediatric patients 5 years of age and older. On 11 December 2017, at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, Emmaus announced the availability of L-Glutamine for treatment of Sickle Cell Disease patients in the US.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Companyâs lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainosâs IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.
MyTomorrows and Emmaus Life Sciences Inc. to Collaborate on Early Access Program for Sickle Cell Disease Treatment in the EU, Turkey, Middle-East and South America